Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
Got $1,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond
07:50am, Thursday, 26'th Oct 2023
AbbVie has good reasons for investors to take a close look at the stock, even though its best-selling drug recently lost patent exclusivity. Tandem Diabetes Care has plenty of room to increase sales,
Why AbbVie (ABBV) is Poised to Beat Earnings Estimates Again
01:32pm, Wednesday, 25'th Oct 2023
AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The 7 Best Forever Stocks to Buy for October 2023
06:15am, Wednesday, 25'th Oct 2023
Navigating the thunderstorm of fluctuating markets, savvy investors anchor their portfolios with the best forever stocks. These stocks have proven resilient in the face of economic uncertainties and c
AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know
06:47pm, Monday, 23'rd Oct 2023
In the latest trading session, AbbVie (ABBV) closed at $144.73, marking a -1.03% move from the previous day.
Earnings Preview: AbbVie (ABBV) Q3 Earnings Expected to Decline
11:17am, Friday, 20'th Oct 2023
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
7 Dividend Stocks to Buy and Hold Forever and Ever
06:45am, Friday, 20'th Oct 2023
Recently, investors searching for dividend stocks to buy have seen more opportunity. Some looking for income over a longer term horizon have flooded into the bond market.
7 Dividend Aristocrats to Batten Down the Hatches
09:15am, Thursday, 19'th Oct 2023
With market uncertainty practically being the only form of certainty available, investors should consider dividend aristocrats. By definition, companies under this category belong in the S&P 500 index
Is AbbVie Stock Too Pricey to Touch Right Now?
07:05am, Thursday, 19'th Oct 2023
AbbVie's valuation is elevated, though it has no major catalysts coming up. It's also seeing sales of its biggest-earning medicine erode rapidly.
AbbVie: The Humira Loss May Be Fully Priced In After All
11:00am, Wednesday, 18'th Oct 2023
The US FDA has already approved two directly interchangeable biosimilars to ABBV's Humira, namely Boehringer Ingelheim's Cyltezo and PFE's ABRILADA. The impact on ABBV's sales may be great, since its
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
10:31am, Wednesday, 18'th Oct 2023
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AbbVie: Q2 Success Sets The Stage For Consistent Growth
01:58pm, Tuesday, 17'th Oct 2023
AbbVie is a leading pharmaceutical company with a strong history and a diverse portfolio of products. The company's flagship product, Humira, has generated significant revenue and it has a pipeline of
3 Supercharged Dividend Stocks to Buy if There's a Stock Market Sell-Off
11:32am, Tuesday, 17'th Oct 2023
AbbVie is a high-yield dividend stock that packs a punch. Stryker is a well-rounded business.
AbbVie: Why You Should Pay Attention To This High-Yielding Dividend King (Rating Downgrade)
09:20am, Tuesday, 17'th Oct 2023
Dividend Kings are the most battle-tested dividend payers on Wall Street, with AbbVie being just one of four in the healthcare sector. The pharmaceutical's 4% dividend yield is covered by both earning
AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why
06:47pm, Monday, 16'th Oct 2023
AbbVie (ABBV) concluded the recent trading session at $147.23, signifying a -0.49% move from its prior day's close.
AbbVie: Successfully Navigating Humira's Patent Cliff With 4% Yield And 270% DGR Since 2014
10:44am, Monday, 16'th Oct 2023
Since its spin-off from Abbott Labs, AbbVie has delivered outstanding performance, surpassing both its parent company and the S&P 500, thanks to the success of Humira. In 2022, AbbVie became the secon
